Chest
Original ResearchAsthmaDedicated Severe Asthma Services Improve Health-care Use and Quality of Life
Section snippets
Results
Baseline demographics are shown in Table 1. TABLE 2, TABLE 3, TABLE 4 compare baseline and follow-up visits in terms of lung function, health-care use, corticosteroid use, and QoL.
The study used a minimum follow-up period of 100 days, with a range of 100 to 833 days and a median value of 286 days. Table 5 divides the cohort into tertiles (1 = shortest and 3 = longest follow-up period) according to the time between baseline and follow-up. Values are presented as No. (%) or median (interquartile
Discussion
The usefulness of a systematic assessment for severe asthma was first evaluated in 1993. A study of 42 patients with difficult-to-control asthma (defined as requiring > 10 mg of prednisolone every other day for ≥ 3 consecutive mo/y) found that following a series of investigations, 31 were deemed no longer difficult to control.7 In addition, it identified two or more contributing factors to the asthma in 80% of subjects. Subsequent studies looking at a systematic assessment have noted similar
Acknowledgments
Author contributions: A. N. M.-G. had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis, including and especially any adverse effects. D. G., L. G. H., C. E. Brightling, R. N., A. H. M., R. C., C. E. Bucknall, and A. N. M.-G. contributed to the study planning and conduct; D. G. contributed to the presentation of plans and data to the group; D. G. and A. N. M.-G. contributed to the data abstraction and
References (12)
- et al.
Difficult-to-control asthma. Contributing factors and outcome of a systematic management protocol
Chest
(1993) - et al.
Design and baseline characteristics of the epidemiology and natural history of asthma: Outcomes and Treatment Regimens (TENOR) study: a large cohort of patients with severe or difficult-to-treat asthma
Ann Allergy Asthma Immunol
(2004) - et al.
Characterization of the severe asthma phenotype by the National Heart, Lung, and Blood Institute's Severe Asthma Research Program
J Allergy Clin Immunol
(2007) - et al.
“Real-life” effectiveness of omalizumab in patients with severe persistent allergic asthma: The PERSIST study
Respir Med
(2009) - et al.
International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma [published correction appears in Eur Respir J. 2014;43(4):1216]
Eur Respir J
(2014) British guideline on the management of asthma. Scottish Intercollegiate Guidelines Network (SIGN) website
Cited by (99)
Factors associated with aeroallergen testing among adults with asthma in a large health system
2023, Journal of Allergy and Clinical Immunology: GlobalPharmaceutical care and asthma: Protocol of an umbrella review of systematic reviews
2023, Farmacia HospitalariaPharmaceutical care and asthma: Protocol of an umbrella review of systematic reviews
2023, Farmacia HospitalariaAsthma in the digital world
2023, Asthma in the 21st Century: New Research AdvancesSystemic corticosteroids in asthma: A call to action from World Allergy Organization and Respiratory Effectiveness Group
2022, World Allergy Organization JournalEffectiveness of Interventions Targeting Treatable Traits for the Management of Obstructive Airway Diseases: A Systematic Review and Meta-Analysis
2022, Journal of Allergy and Clinical Immunology: In PracticeCitation Excerpt :The abstracts of 5751 articles were screened to identify 27 articles for the full-text analysis. After removing 16 articles29-44 not meeting the predefined inclusion criteria, 11 studies6-16 were included in the final systematic review. The 7 controlled trials6,8,10-14 were included in the meta-analyses (Figure 1).
FUNDING/SUPPORT: The authors have reported to that no funding was received for this study.
originally published Online First March 19, 2015.